论文部分内容阅读
目的探讨血浆单核细胞趋化因子-1(MCP-1)及基质金属蛋白酶-9(MMP-9)在急性冠状动脉综合征(ACS)发病机制中的作用,以及阿托伐他汀对炎症介质的干预作用。方法入选冠状动脉造影确诊的ACS患者70例作为ACS组,冠状动脉造影结果正常受试者40例作为对照组,采用酶联免疫吸附法(ELISA)检测所有受试者术前空腹MCP-1及MMP-9血浆水平,ACS组患者口服阿托伐他汀4周后再次检测空腹MCP-1及MMP-9血浆水平。结果ACS组血浆MCP-1、MMP-9水平为(24.13±6.24)ng/L、(19.75±4.63)mg/L,与对照组(18.97±5.87)ng/L和(15.45±4.38)mg/L比较,差异有高度统计学意义(P<0.01),服用阿托伐他汀4周后ACS组血浆MCP-1及MMP-9血浆水平明显下降(P<0.01)。结论炎症反应可能参与ACS的发病过程,阿托伐他汀在抑制ACS患者炎症反应、稳定动脉粥样斑块,减少急性心血管事件方面可能有一定的作用。
Objective To investigate the role of monocyte chemoattractant protein-1 (MCP-1) and matrix metalloproteinase-9 (MMP-9) in the pathogenesis of acute coronary syndrome (ACS) and the effect of atorvastatin on inflammatory mediators The role of intervention. Methods Seventy patients with ACS diagnosed by coronary angiography as ACS group and 40 normal subjects with coronary angiography as control group. The levels of MCP-1 and MCP-1 in preoperative fasting plasma were measured by enzyme-linked immunosorbent assay (ELISA) Plasma levels of MMP-9 and plasma levels of fasting MCP-1 and MMP-9 were measured again in patients in the ACS group 4 weeks after oral administration of atorvastatin. Results Compared with the control group (18.97 ± 5.87) ng / L and (15.45 ± 4.38) mg / L, the levels of MCP-1 and MMP-9 in ACS group were significantly lower than those in control group (24.13 ± 6.24) ng / (P <0.01). The plasma levels of MCP-1 and MMP-9 in ACS group were significantly decreased after 4 weeks of atorvastatin treatment (P <0.01). Conclusion Inflammatory reaction may be involved in the pathogenesis of ACS. Atorvastatin may play an important role in inhibiting inflammatory reaction, stabilizing atherosclerotic plaque and reducing acute cardiovascular events in patients with ACS.